Condition: HER2-positive Locally Advanced or Metastatic Biliary Tract Cancer · Sponsor: Suzhou Suncadia Biopharmaceuticals Co., Ltd.
This study is an open, multicenter Phase II clinical trial to evaluate the efficacy and safety of the SHR-A1811 combination in HER2 positive patients with locally advanced or metastatic biliary tract cancer.
This description comes directly from the study's public registry record.
Tingting Lei, BM · +86-18610051325 · tingting.lei.tl6@hengrui.com
Always discuss trial participation with your own doctor first.
| Affiliated Cancer Hospital of Harbin Medical University | Harbin, Heilongjiang, China | Recruiting |
| Zhongshan Hospital, Fudan University | Shanghai, Shanghai Municipality, China | Recruiting |
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT06778031